Phase II Study to Evaluate Efficacy and Safety of RP101 in Combination With Gemcitabine
Public ClinicalTrials.gov record NCT00550004. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Randomized, Double Blind, Placebo Controlled, Phase 2 Study Evaluating the Efficacy & Safety of RP101 or Placebo in Combination With Gemcitabine Administered as First-Line Treatment to Subjects With Unresectable, Locally Advanced, or Metastatic Pancreatic Adenocarcinoma
Study identification
- NCT ID
- NCT00550004
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- SciClone Pharmaceuticals
- Industry
- Enrollment
- 153 participants
Conditions and interventions
Conditions
Interventions
- Gemcitabine (1000 mg/m2) Drug
- RP101 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 31, 2007
- Primary completion
- Jul 31, 2009
- Completion
- Sep 30, 2009
- Last update posted
- Jun 7, 2011
2007 – 2009
United States locations
- U.S. sites
- 16
- U.S. states
- 11
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Arizona Medical Center, Arizona Cancer Center | Tucson | Arizona | 85724 | — |
| Tower Research Foundation at Tower Oncology | Beverly Hills | California | 90211 | — |
| University of California at San Francisco | San Francisco | California | 94110 | — |
| Integrated Community Oncology Network, LLC | Jacksonville | Florida | 32256 | — |
| Lakeland Regional Cancer Center | Lakeland | Florida | 33805 | — |
| Mid Dakota Clinic | Bismarck | North Dakota | 58501 | — |
| Gabrail Cancer Center | Canton | Ohio | 44718 | — |
| Signal Point Clinical Research Center, LLC | Middletown | Ohio | 45042 | — |
| Providence Portland Medical Center | Portland | Oregon | 97231 | — |
| St. Luke's Cancer Center | Bethlehem | Pennsylvania | 18015 | — |
| Baylor College of Medicine | Houston | Texas | 77030 | — |
| South Texas Oncology and Hematology, PA | San Antonio | Texas | 78207 | — |
| Utah Cancer Specialists | Salt Lake City | Utah | 84106 | — |
| University of Washington | Seattle | Washington | 98109-1023 | — |
| Cancer Care Northwest | Spokane | Washington | 99202 | — |
| Medical College of Wisconsin, Froedtert Multi-Disciplinary Cancer Center | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 39 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00550004, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 7, 2011 · Synced May 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00550004 live on ClinicalTrials.gov.